News

Pulmonary Fibrosis Healing May Be Promoted By “Beneficial Inflammation”

Inflammation has long been considered an integral element of the biological process that leads to deadly scarring in idiopathic pulmonary fibrosis, one of a broad category of lung diseases classified as Interstitial lung disease (ILD) that includes more than 130 disorders characterized by scarring (i.e. fibrosis) and/or inflammation…

Idiopathic Pulmonary Fibrosis Found To Cause Evolutionarily Ancient “Master” Protein That Protects Injured Cells, Repairs Damage

Researchers at Brown University in Providence, Rhode Island and collaborating institutions report having achieved some progress in the battle against idiopathic pulmonary fibrosis (IPF), a devastating lung disease that afflicts millions of people worldwide. Two experimental drugs have recently showed promise in clinical trials, and now a study last…

PFF Conducting Survey on PF Patients’ Needs For FDA Meeting

The Pulmonary Fibrosis Foundation (PFF) recently submitted research data about more than 1,100 patients who suffer from pulmonary fibrosis (PF) to the U.S. Food and Drug Administration (FDA), in order to participate in the Patient-Focused Drug Development Meeting for Idiopathic Pulmonary Fibrosis. The meeting will take place on September…

PFF and CPF Documentary About Idiopathic Pulmonary Fibrosis to Air on Discovery Channel

  Pharmaceutical company Boehringer Ingelheim Pharmaceuticals, Inc. is sponsoring the documentary Every Breath Counts: Idiopathic Pulmonary Fibrosis, which will air on the Discovery Channel on September 13th and 27th at 8:00 am ET/PT, and can also be viewed at www.everybreathcountsfilm.com. The documentary was created in collaboration with the Pulmonary…

Phase 1 Clinical Trial May Suggest Positive Clues On Drug Candidate For IPF

Pacific Therapeutics Ltd., a pharmaceutical company focused on the reformulation of existing approved drugs, recently announced the end of an initial phase 1 trial of its drug candidate for Idiopathic Pulmonary Fibrosis, PTL-202, combined with an important antioxidant amino acid, with positive signs on its effectiveness, low side effects,…

Idiopathic Pulmonary Fibrosis Sufferers In Ontario Finally Given Access To Key Therapy

Citizens of Canada’s largest province afflicted by idiopathic pulmonary fibrosis (IPF) have finally been given access to a key IPF therapy after a protracted two-year fight. IPF patients in Canada’s other provinces hope publicly-funded access to first and only treatment isn’t far behind. Ontario’s Executive Officer has announced that Esbriet…